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Objectives This study used the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) database to as-
sess the impact of background beta-blocker dose on response to ivabradine.
Background In systolic heart failure, reduction in relatively high heart rates improves clinical outcomes when achieved with
beta-blockers and even more so when the sinus node inhibitor ivabradine also is added.
Methods Among patients with systolic heart failure, sinus rhythm, and heart rate70 beats/min on recommended background ther-
apy, maximally tolerated beta-blocker doses were subgrouped as no beta-blocker,25%, 25% to50%, 50% to100%,
and 100% of European Society of Cardiology–suggested target doses. The impact of ivabradine on cardiovascular death or
heart failure hospitalization (primary endpoint) was analyzed in each subgroup as time-to-first event using Cox models ad-
justed for heart rate. The statistical models assessed heterogeneity and trend of the treatment effect across subgroups, and
an additional analysis was made adjusting for the interaction of randomized treatment with baseline heart rate.
Results The primary endpoint and heart failure hospitalizations were significantly reduced by ivabradine in all subgroups
with 50% of target beta-blocker dose, including no beta-blocker (p  0.012). Despite an apparent trend to re-
duction in treatment-effect magnitude with increasing beta-blocker dose, no variation in treatment effect was
seen in general heterogeneity interaction tests (p  0.35). Across beta-blocker subgroups, treatment effect was
borderline nonsignificant only for the primary endpoint (p  0.056), and significance was further lost after ad-
justing for interaction between baseline heart rate and ivabradine effect (p  0.14).
Conclusions The magnitude of heart rate reduction by beta-blocker plus ivabradine, rather than background beta-blocker
dose, primarily determines subsequent effect on outcomes. (Effects of ivabradine on cardiovascular events in
patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year ran-
domised double-blind placebo-controlled international multicentre study; ISRCTN70429960) (J Am Coll Cardiol
2012;59:1938–45) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.01.020During the last 20 years, the treatment of symptomatic heart
failure with systolic dysfunction has improved markedly, and the
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nation of neurohormonal antagonists with focus on modulation of
the renin-angiotensin-aldosterone system and the sympathetic
nervous system (3). Among those agents, beta-receptor antago-
nists have emerged as being particularly important.
See page 1946
The mechanism for the effects of beta-blockers is unclear,
but an association between the improvement of mortality
and the degree of drug-induced heart rate reduction has
been reported (4). Heart rate is a risk marker in the general
population (5), as well as in those with coronary artery
disease (6). In patients with systolic heart failure and in
sinus rhythm included in the SHIFT (Systolic Heart failure
treatment with the If inhibitor ivabradine Trial) study, heart
rate has been identified as a modifiable risk factor (7). Heart
rate 70 beats/min in patients treated with a beta-blocker,
as well as in those without a beta-blocker because of lack of
tolerability of the drug, was found to be strongly related to
the risk of worsening of heart failure or death due to heart
failure. In SHIFT, reduction of heart rate by ivabradine,
administered in addition to beta-blockers when heart rate
exceeded 70 beats/min on beta-blockers alone, reduced
subsequent adverse outcomes (8). There was no interaction
in the effect of ivabradine between patients not taking a
beta-blocker versus those treated (8). A remaining clinical
question is whether beta-blocker dose at randomization
impacts the response to ivabradine. The present analysis was
initiated to explore this question using the SHIFT database.
Methods
Design and treatment. SHIFT was a randomized, double-
blind, placebo-controlled, parallel-group clinical trial in
patients with moderate-to-severe heart failure and left
ventricular systolic dysfunction, undertaken in 677 centers
in 37 countries. The study design has been reported else-
where (9). In brief, patients included in the trial were men
or women 18 years and older with stable symptomatic
chronic heart failure of 4 or more weeks’ duration with left
ventricular ejection fraction 35%, who had been admitted
to hospital for worsening heart failure within the previous
12 months, and who were in sinus rhythm and with a
resting heart rate of 70 beats/min (measured by 12-lead
electrocardiogram on 2 consecutive visits). Patients were
randomized to receive treatment with ivabradine or placebo.
The starting dose of study drug was 5 mg twice daily. After
a 14-day titration period, the dose was increased to 7.5 mg
twice daily, unless the resting heart rate was 60 beats/min or
lower. The dose was adjusted throughout the study to 7.5,
5, or 2.5 mg twice daily according to resting heart rate and
tolerability. At randomization and throughout the study,
participants were expected to be on evidence-based medication
for heart failure at guidelines-suggested doses if tolerated.
When a participant was not on a beta-blocker or was not on bthe guidelines-suggested target
dose, the investigator was required
to provide a specific reason in a
dedicated case-report form.
The aim of the current analysis
was: to compare characteristics of
participants by baseline beta-
blocker status; to assess reasons
for not taking a beta-blocker or
for not taking the target dose; to
identify the baseline factors inde-
pendently predicting those not
taking a beta-blocker or, among those on a beta-blocker, not
taking at least 50% of the target dose; and to investigate the
effect of ivabradine treatment on study outcomes across the
range of beta-blockers and doses. To this end, we catego-
rized participants as taking or not taking a beta-blocker at
randomization and subdivided those taking a beta-blocker
into categories defined by the percentage of the target dose
they were taking. These categories were defined as 25%,
25% to 50%, 50% to 100%, and 100% of the target dose
as defined by the European Society of Cardiology (ESC)
guidelines (10). A total of 107 of the 6,505 randomized
participants were taking a beta-blocker that was not recom-
mended in the guidelines and hence could not be catego-
rized. These 107 participants were excluded from all anal-
yses reported in this paper, leaving a total of 6,398 for
analysis.
All study endpoints were adjudicated by an independent
endpoint validation committee.
The study was approved by the ethics committee or
institutional review board of every site, and each study
participant had provided formal informed consent.
Statistical methods. Baseline characteristics of the patients
at randomization were summarized as count (%) for cate-
gorical variables and mean  SD for continuous variables.
he distributions of these variables across the beta-blocker
ategories were compared by chi-square tests and analysis of
ariance for categorical and continuous variables, respec-
ively, initially using tests of general heterogeneity and then
sing trend tests. The distribution of reasons given for a
articipant not to be taking a beta-blocker or, if taking a
eta-blocker, not taking the target dose, were tabulated by
eta-blocker category. The baseline factors independently
ssociated with not taking a beta-blocker versus taking a
eta-blocker were analyzed by fitting a multivariable step-
ise logistic regression model to those factors significantly
ssociated with not taking a beta-blocker in univariate
nalysis (p  0.05). Results are given as odds ratios, 95%
onfidence intervals, and p values calculated from the Wald
tatistic. A similar analysis was conducted in those taking a
eta-blocker to identify the factors associated with taking at
east half of the target dose.
The effect of ivabradine treatment on heart rate reduction
as studied in the 25 subgroups defined by baseline beta-
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
CI  confidence interval
COPD  chronic
obstruction pulmonary
disease
ESC  European Society
of Cardiologylocker categories and heart rate categories (as previously
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to 75 beats/min, 75 to 80 beats/min, 80 to 87
beats/min, 87 beats/min). The mean differences between
the heart rate changes from baseline to 28 days for the
placebo group and the ivabradine group were calculated and
evaluated using 3-way analysis of variance (with treatment
group, beta-blocker category, and baseline heart rate cate-
gory as factors).
The impact of ivabradine treatment versus placebo on
the primary study outcome of cardiovascular death or
hospital admission for worsening heart failure and its
components, cardiovascular death, and hospital admis-
sion for worsening heart failure, was determined in each
beta-blocker category using time-to-first event survival
analysis-based Cox proportional hazards models contain-
ing treatment as a factor and with adjustment for prog-
nostic factors previously used (age, left ventricular ejec-
tion fraction, estimated glomerular filtration rate, New
York Heart Association functional class, ischemic etiol-
ogy [yes/no], and systolic blood pressure) (7). Hazard
ratios for ivabradine treatment relative to placebo were
estimated with 95% confidence intervals and p values
calculated from the Wald statistic. Analyses were re-
peated with and without adjustment for baseline heart
rate as a continuous variable. There were no qualitative
differences in the models unadjusted for heart rate.
Results are reported only for the models adjusted for
heart rate. A number of additional models were fitted.
First, the differences in treatment effect were analyzed
using a general test of heterogeneity across the 5 beta-
blocker categories, then with a test for trend in the
magnitude of the treatment effect across the beta-blocker
categories. In addition, since we have previously demon-
strated evidence of a statistically significant interaction
between baseline heart rate and the effect of ivabradine
(7), we fitted models adjusting also for this interaction.
The motivation for this analysis is that the interaction
between baseline heart rate and ivabradine treatment
suggests that the impact of treatment is greatest in those
with the highest baseline heart rate; hence, this might
explain why the effect of ivabradine is greatest in those on
the lowest dose or no beta-blocker where baseline heart
rate is greatest. Finally, to explore the effect of beta-
blocker dose on the effects of ivabradine in those taking
a beta-blocker, the main analysis was repeated omitting
those not taking a beta-blocker.
Results
Baseline characteristics of participants arranged by beta-
blocker dose category are given in Table 1. In univariate
analysis, not being on a beta-blocker or being on a low dose
of beta-blocker was associated with older age, being Asian,
and having a lower body mass index, a higher resting heart
rate, lower blood pressure, lower ejection fraction, lower
rates of taking an angiotensin-converting enzyme (ACE)inhibitor or statin or using devices, and higher rates of
taking diuretics or digoxin. Not taking a beta-blocker was
particularly associated with a history of chronic obstructive
pulmonary disease (COPD), asthma, or peripheral arterial
disease and with taking amiodarone. Patients taking calcium
channel–blocking drugs were more likely not to be taking a
beta-blocker, but if taking a beta-blocker, they were more
likely to be on a high beta-blocker dose.
Background beta-blocker dosing. Reasons given by inves-
tigators for not administering a beta-blocker or for not
reaching the target dose are listed in Table 2. Most frequent
reasons for not administering a beta-blocker were COPD,
hypotension, asthma, or cardiac decompensation. In those
taking a beta-blocker, but not achieving the target dose, the
distribution of reasons across the 3 categories were similar to
the reasons for beta-blocker nonuse, i.e., hypotension,
fatigue, dyspnea, dizziness, cardiac decompensation, and
excessive bradycardia.
Independent factors associated with beta-blocker use are
given in Table 3. Factors associated with a lower likelihood
of taking a beta-blocker are the comorbidities of COPD or
asthma, having low blood pressure, having a high heart rate,
being older, and taking amiodarone, a calcium channel
blocker, or digoxin.
In Table 3, for those taking a beta-blocker, the indepen-
dent factors associated with a relatively low likelihood of
taking at least 50% of the target dose are a history of
COPD, a lower blood pressure, a higher heart rate, being
older, being treated with amiodarone or digoxin, or not
being treated with a calcium channel blocker.
The placebo-corrected effects of ivabradine on heart rate,
by categories of baseline beta-blocker doses and baseline
heart rate, are illustrated in Figure 1. The analysis of
variance model did not provide any evidence of an interac-
tion between beta-blocker dose and baseline heart rate on
the placebo-corrected effect of ivabradine on change in heart
rate. However, there was evidence of a clear effect of
baseline heart rate (p  0.0001), with greatest changes in
heart rate at the highest baseline heart rates, but no strong
evidence of an additional effect of beta-blocker category
(p  0.073). In this model, the effect of the interaction of
ivabradine treatment with baseline heart rate remained
significant (p  0.03). In analyses of the placebo and
ivabradine groups separately, both baseline heart rate and
baseline beta-blocker category independently influence
ivabradine-mediated change in heart rate.
Effects of ivabradine. The effects of treatment with ivabra-
dine on the primary endpoint or its major secondary
endpoints are given in Table 4. Nominally statistically
ignificant reductions in the primary endpoint or hospital
dmissions for worsening heart failure are demonstrated for
hose not on beta-blocker and each category of beta-blocker
ose 50% of the target dose (p  0.012, p  0.007, and
 0.029; and p 0.003, p 0.005, and p 0.009 for the
primary endpoint and hospital admissions for worsening
heart failure, respectively). Despite these results and the
tion fra
d
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effect with increasing beta-blocker dose, there was no
evidence of variation in treatment effect in the general
heterogeneity interaction tests (primary composite endpoint
Baseline Characteristics Split by Baseline Beta-Blocker CategoryTable 1 Baseline Characteristics Split by Baseline Beta-Blocke
Overall
(n  6,398)
None
(n  685)
<25%
(n  908)
Age, yrs 60.3 11.4 64.0 10.9 61.2 11.8
Male 4,890 (76.4%) 512 (74.7%) 705 (77.6%)
Ethnic origin
White 5,670 (88.6%) 574 (83.8%) 695 (76.5%)
Asian 530 (8.3%) 96 (14.0%) 188 (20.7%)
Other 198 (3.1%) 15 (2.2%) 25 (2.8%)
Current smokers 1,106 (17.3%) 131 (19.1%) 157 (17.3%)
Body mass index, kg/m2 28.0 5.1 27.0 5.1 26.4 4.8
Resting heart rate,
beats/min
79.9 9.6 84.2 12.1 80.6 9.9
Systolic blood pressure,
mm Hg
121.5 16.0 121.1 17.3 117.1 16.2
Diastolic blood pressure,
mm Hg
75.6 9.5 74.1 9.9 73.8 9.7
LVEF, % 29.0 5.2 28.7 5.4 28.1 5.4
eGFR, ml/min/1.73 m2 74.6 23.0 71.5 22.8 74.4 26.1
NYHA functional class
II 3,110 (48.6%) 287 (41.9%) 419 (46.1%)
III 3,175 (49.6%) 376 (54.9%) 469 (51.7%)
IV 111 (1.7%) 22 (3.2%) 20 (2.2%)
Ischemic heart failure 4,333 (67.2%) 444 (64.8%) 571 (62.9%)
History of
MI 3,597 (56.2%) 350 (51.1%) 454 (50.0%)
Hypertension 4,226 (66.1%) 434 (63.4%) 498 (54.8%)
Diabetes 1,937 (30.3%) 197 (28.8%) 260 (28.6%)
Stroke 511 (8.0%) 64 (9.3%) 59 (6.5%)
Atrial fibrillation or
flutter
510 (8.0%) 61 (8.9%) 70 (7.7%)
Dyslipidemia 1,204 (18.8%) 98 (14.3%) 145 (16.0%)
COPD 721 (11.3%) 224 (32.7%) 95 (10.5%)
Asthma 174 (2.7%) 74 (10.8%) 15 (1.7%)
PAD 402 (6.3%) 66 (9.6%) 58 (6.4%)
Coronary artery
disease
4,636 (72.5%) 476 (69.5%) 605 (66.6%)
ACE 5,028 (78.6%) 503 (73.4%) 664 (73.1%)
ARB 913 (14.3%) 129 (18.8%) 129 (14.2%)
ACE/ARB 5,826 (91.1%) 620 (90.5%) 785 (86.5%)
Diuretic 5,325 (83.2%) 589 (86.0%) 786 (86.6%)
Antialdosterone agent 3,883 (60.7%) 399 (58.2%) 591 (65.1%)
Statin 3728 (58.3%) 327 (47.7%) 459 (50.6%)
Calcium-channel
blockers
519 (8.1%) 85 (12.4%) 42 (4.6%)
Amiodarone 186 (2.9%) 50 (7.3%) 23 (2.5%)
Digoxin 1393 (21.8%) 207 (30.2%) 253 (27.9%)
Devices 243 (3.8%) 23 (3.4%) 28 (3.1%)
CRT 72 (1.1%) 9 (1.3%) 11 (1.2%)
ICD 206 (3.2%) 15 (2.2%) 23 (2.5%)
Values are mean  SD or n (%).
ACE  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; COPD 
glomerular filtration rate; ICD  implantable cardioverter-defibrillator; LVEF  left ventricular ejec
isease.p  0.35) in which adjustment was made for baseline heart 0rate. In the test formally investigating trends in the treat-
ment effects across beta-blocker category, there were no
statistically significant results and a borderline nonsignifi-
cant result only for the primary composite endpoint (p 
egory
-Blocker Dose
p Value
Heterogeneity
p Value
Trend
5%–<50%
 1,624)
50%–<100%
(n  1,693)
>100%
(n  1,488)
0.5 11.5 59.9 11.1 58.5 11.1 0.001 0.001
54 (77.2%) 1,292 (76.3%) 1,127 (75.7%) 0.594 0.809
23 (87.6%) 1,599 (94.4%) 1379 (92.7%) 0.001 0.001
65 (10.2%) 59 (3.5%) 22 (1.5%)
36 (2.2%) 35 (2.1%) 87 (5.8%)
85 (17.5%) 304 (18.0%) 229 (15.4%) 0.201 0.068
7.4 4.8 28.8 4.9 29.2 5.2 0.001 0.001
9.5 9.4 79.1 8.9 78.9 8.6 0.001 0.001
0.0 16.1 122.5 15.4 125.0 14.7 0.001 0.001
5.0 9.5 76.2 9.2 77.6 9.0 0.001 0.001
8.9 5.2 29.4 4.9 29.3 5.0 0.001 0.001
4.2 22.4 74.3 21.5 77.0 22.9 0.001 0.001
21 (50.6%) 849 (50.1%) 734 (49.3%) 0.001 0.001
68 (47.3%) 826 (48.8%) 736 (49.5%)
33 (2.0%) 18 (1.1%) 18 (1.2%)
20 (69.0%) 1,210 (71.5%) 988 (66.4%) 0.001 0.024
27 (57.1%) 1,027 (60.7%) 839 (56.4%) 0.001 0.001
29 (63.4%) 1,183 (69.9%) 1,082 (72.7%) 0.001 0.001
74 (29.2%) 528 (31.2%) 478 (32.1%) 0.207 0.024
28 (7.9%) 152 (9.0%) 108 (7.3%) 0.098 0.719
32 (8.1%) 140 (8.3%) 107 (7.2%) 0.664 0.301
83 (17.4%) 327 (19.3%) 351 (23.6%) 0.001 0.001
74 (10.7%) 152 (9.0%) 76 (5.1%) 0.001 0.001
29 (1.8%) 32 (1.9%) 24 (1.6%) 0.001 0.001
91 (5.6%) 110 (6.5%) 77 (5.2%) 0.001 0.002
92 (73.4%) 1,281 (75.7%) 1,082 (72.7%) 0.001 0.001
76 (78.6%) 1,374 (81.2%) 1,211 (81.4%) 0.001 0.001
13 (13.1%) 214 (12.6%) 228 (15.3%) 0.001 0.103
70 (90.5%) 1,560 (92.1%) 1,391 (93.5%) 0.001 0.001
46 (82.9%) 1,400 (82.7%) 1,204 (80.9%) 0.002 0.001
08 (62.1%) 1,013 (59.8%) 872 (58.6%) 0.009 0.095
31 (57.3%) 1,062 (62.7%) 949 (63.8%) 0.001 0.001
05 (6.5%) 138 (8.2%) 149 (10.0%) 0.001 0.281
51 (3.1%) 40 (2.4%) 22 (1.5%) 0.001 0.001
54 (21.8%) 301 (17.8%) 278 (18.7%) 0.001 0.001
52 (3.2%) 65 (3.8%) 75 (5.0%) 0.050 0.010
20 (1.2%) 12 (0.7%) 20 (1.3%) 0.445 0.716
46 (2.8%) 56 (3.3%) 66 (4.4%) 0.021 0.001
ic obstruction pulmonary disease; CRT  cardiac resynchronization therapy; eGFR  estimated
ction; MI  myocardial infarction; NYHA  New York Heart Association; PAD  peripheral arteryr Cat
Beta
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1,4
1
2
2
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7
2
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8
7
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chron.056). After adjusting for the previously identified interac-
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with ivabradine, the weak evidence of heterogeneity of
treatment effect associated with beta-blocker dose was
further diluted (p 0.14). In patients with a beta-blocker at
baseline, there was no evidence of a trend across the 4 dose
categories even in the analysis adjusting only for baseline
heart rate (p 0.073 for the primary endpoint, p 0.23 for
hospital admission for worsening heart failure, and p 0.19
for cardiovascular death).
Discussion
The present analysis indicates that the effects of ivabradine
on the primary clinical outcome of SHIFT, and its compo-
nents, were not significantly impacted by beta-blocker dose.
Any borderline nonsignificant trends were significantly
weakened by adjustment for the previously identified inter-
action between baseline heart rate and ivabradine treatment.
This suggests that any impact of background beta-blocker
treatment on the effects of ivabradine are, if anything,
marginal and that the critical factor driving the benefits of
ivabradine treatment is heart rate.
Reasons for Not Taking a Beta-Blocker or Not Taking Target DoseTable 2 Reasons for Not Taking a Beta-Blocker or Not Taking T
None (n  685) <25% (n 
Hypotension 127 (19%) 425 (47
Fatigue 37 (5%) 289 (32
Dyspnea — 135 (15
Dizziness 21 (3%) 97 (11
Bradycardia 20 (3%) 48 (5%
Cardiac decompensation 54 (8%) 101 (11
Other 81 (12%) 67 (7%
COPD 235 (34%) —
Asthma 74 (11%) —
Raynaud’s or PAD 36 (5%) —
Values are n (%). Data are presented by categories of the percentage taking target dose. Note: M
Abbreviations as in Table 1.
Results of Multivariable Stepwise Logistic RegrTable 3 Results of Multivariable Stepwise L
On a
Not o
OR (
History of COPD 0.23 (0
History of asthma 0.13 (0
DBP, per 5 mm Hg lower 0.90 (0
SBP, 10 mm Hg lower
Heart rate, per 5 beats/min higher 0.81 (0
Age, per 5 yrs older 0.83 (0
Treatment
Amiodarone 0.29 (0
Calcium-channel blocker 0.52 (0
Digoxin 0.58 (0
The multivariable stepwise logistic regression was used to identify inde
a beta-blocker at baseline and to identify independent predictors of bei
shown are odds ratios (ORs) and 95% confidence intervals (CIs). An O
least 50% of target dose as appropriate. N/A indicates term is not applicable
COPD  chronic obstructive pulmonary disease; DBP  diastolic blood preBeta-blockers have well-documented direct effects on
cardiovascular and pulmonary function as well as in gener-
ating symptoms, e.g., fatigue and dizziness (11,12). There-
fore, it is anticipated that differences in background beta-
blocker doses would be related to different demographic
characteristics in SHIFT participants, such as age or pul-
monary comorbidities. In addition, several of these factors
have prognostic implications, e.g., age, blood pressure, and
left ventricular systolic function (10). The use of devices was
low by study design and was addressed in the main SHIFT
paper (8). Among the patients included in SHIFT, differ-
ences in distribution of comorbidities among groups ar-
ranged by background beta-blocker dose are particularly
interesting and potentially important in terms of the relation
between beta-blocker doses and outcome. For this reason,
to minimize outcome differences that might be due to
differences in beta-blocker dosing, SHIFT investigators
were exhorted to include patients at maximized beta-blocker
dose, and the SHIFT protocol prospectively required ascer-
taining and recording reasons for not using a beta-blocker at
all or not reaching guideline-recommended target doses
t Dose
Beta-Blocker Dose
25%–<50% (n  1,624) 50%–<100% (n  1,693)
717 (44%) 743 (44%)
543 (33%) 514 (30%)
226 (14%) 225 (13%)
209 (13%) 206 (12%)
106 (7%) 105 (6%)
144 (9%) 122 (7%)
142 (9%) 209 (12%)
— —
— —
— —
n 1 reason could be given for not taking target dose of beta-blocker.
nic Regression
Blocker vs.
eta-Blocker
On at Least 50%
of the Target Dose
I), p Value OR (95% CI), p Value
28),0.0001 0.67 (0.55–0.80),0.0001
19),0.0001 N/A
95),0.0001 N/A
A 0.82 (0.79–0.85),0.0001
84),0.0001 0.95 (0.92–0.97), 0.0002
87),0.0001 0.91 (0.89–0.94),0.0001
42),0.0001 0.63 (0.44–0.89), 0.0093
69),0.0001 1.33 (1.07–1.64), 0.0090
70),0.0001 0.75 (0.65–0.85),0.0001
t factors associated with being on a beta-blocker versus not being on
least 50% of the target dose among those taking a beta-blocker. Data
0 indicates reduced likelihood of being on a beta-blocker or taking atarge
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collected at baseline in a specially designated case report
form (9). Thus, intensive effort was made to optimize
beta-blocker usage in SHIFT. Despite this effort, only
about one-quarter of patients reached recommended target
doses, and approximately one-half achieved at least 50% of
Figure 1 Baseline Heart Rate by Background Dose of Beta-Bloc
Ivabradine–placebo difference in mean change in heart rate from baseline to 28 d
and heart rate categories.
Estimates of the Effects of Randomized Treatment by Category ofTable 4 Estimates of the Effects of Randomized Treatment by
Ivabradine Placebo
(
HR (9
Primary endpoint
No beta-blocker 101 (29.4%) 134 (39.3%) 0.71 (0
Beta-blocker 25% 148 (30.8%) 171 (40.0%) 0.74 (0
Beta-blocker 25% to 50% 204 (26.2%) 260 (30.8%) 0.81 (0
Beta-blocker 50% to 100% 181 (21.6%) 212 (24.8%) 0.88 (0
Beta-blocker 100% 149 (20.1%) 150 (20.1%) 0.99 (0
Hospital admission for
worsening heart failure
No beta-blocker 65 (18.9%) 98 (28.7%) 0.62 (0
Beta-blocker 25% 99 (20.6%) 125 (29.3%) 0.68 (0
Beta-blocker 25% to 50% 131 (16.8%) 183 (21.7%) 0.74 (0
Beta-blocker 50% to 100% 124 (14.8%) 154 (18.0%) 0.83 (0
Beta-blocker 100% 89 (12.0%) 106 (14.2%) 0.84 (0
CV death
No beta-blocker 63 (18.3%) 81 (23.8%) 0.80 (0
Beta-blocker 25% 84 (17.5%) 96 (22.5%) 0.82 (0
Beta-blocker 25% to 50% 119 (15.3%) 134 (15.9%) 0.95 (0
Beta-blocker 50% to 100% 96 (11.5%) 101 (11.8%) 0.99 (0
Beta-blocker 100% 80 (10.8%) 74 (9.9%) 1.08 (0
Values are n (%), unless otherwise indicated. All analyses are adjusted for baseline heart rate, age, le
class, ischemic etiology (yes/no), and systolic blood pressure. Three tests are carried out: 1) a gene
test adjusted for the interaction between baseline heart rate and treatment (†).
CV  cardiovascular.the target dose. Consequently, it is unclear whether differ-
ences in outcome are due to differences in beta blocker doses
or differences in the characteristics that limited beta-blocker
up-titration.
Nonetheless, the achieved beta-blocker doses in SHIFT
are lower than in the landmark beta-blocker studies (13–15)
each of the 25 subgroups defined by baseline beta-blocker
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based. However, in those beta-blocker trials, despite a
forced titration of the beta-blocker, a considerable number
of patients could not reach the target dose at the end of the
titration phase (16–18). In addition, a substantial number of
patients could not be maintained on the doses achieved after
the titration phase and had to reduce or interrupt the
treatment due to intolerance during the maintenance phase
(18). Moreover, lower doses of beta-blockers in SHIFT
might reasonably be expected because treatment patterns
and adjunctive therapies have changed in the many years
since the landmark beta-blocker trials were performed,
for example, with the addition of direct aldosterone
antagonism, not regularly employed during the beta-
blocker trials.
Thus, it is not surprising that the beta-blocker doses used
in SHIFT are thoroughly consistent with doses employed
among patients with heart failure in recent international
surveys and randomized studies. For example, in the recent
CIBIS-ELD (Cardiac Insufficiency Bisoprolol Study in
Elderly) study, Dungen et al. (19) compared the effects of
bisoprolol and carvedilol in a randomized trial. Dosing was
achieved by forced titration, and target doses were defined,
as in SHIFT, according to the ESC guidelines. At least 50%
of the target dose was achieved in 55% of the patients, a
proportion very similar to that observed in SHIFT. The
recent European survey by Maggioni et al. (20) in 3,226
patients with chronic heart failure showed that 87% of
patients with heart failure were treated with a beta-blocker,
but the target doses of carvedilol, bisoprolol, and meto-
prolol, as defined by the ESC guidelines, were only reached
in 37%, 21%, and 21% of patients, respectively. In another
study in primary care in Sweden, pharmacological therapy
was optimized to the highest possible dose in relation to
ESC recommendations (21). However, beta-blocker use in
doses 50% was possible in only 62% of patients, and in
57% of patients when the combination of a beta-blocker, an
ACE inhibitor, or an angiotensin receptor blocker was
considered. In another study in primary care from Scotland,
a beta-blocker was used in only 62% and, when used, at least
50% of target doses were reached in 69% and target doses in
34% (22). Based on these experiences, the proportion of
patients in contemporary clinical practice (featuring multi-
ple background drugs) who can be titrated to target beta-
blocker doses seems to be in the range of 20% to 40%.
For the primary composite outcome in SHIFT, the effect
of ivabradine was not significantly associated with the
baseline dose of beta-blocker treatment, even in the most
statistically powerful trend test, and no association was
evident when a general test for interaction was performed.
When analysis was adjusted for the previously established
interaction between baseline heart rate and ivabradine treat-
ment, any trend that was evident was further weakened. No
suggestion of a significant trend was apparent when the
analysis was restricted to those taking a beta-blocker. The
placebo-corrected treatment effect of ivabradine on heartrate was significantly related to baseline heart rate, but not
to beta-blocker dose. Thus, baseline heart rate was the most
important contributor to the treatment effect. In the overall
trial, the primary driver of the benefit of ivabradine treat-
ment was the effect on hospitalization for heart failure, with
no significant benefit on reduction in cardiovascular mor-
tality. Hence, it is worthy of note that there was at least a
trend to ivabradine-mediated benefit in reducing heart
failure admissions for all categories of beta-blocker treat-
ment, and there was no evidence of heterogeneity of effect
across the beta-blocker doses for this outcome.
Moreover, although reduction of heart rate by ivabradine
above what is achieved with a beta-blocker and the effect on
outcomes by ivabradine have a borderline, nominally non-
significant relationship to the dose of background beta-
blocker therapy, our analysis suggests that this unconfirmed
trend may be explained by the confounding impact of the
interaction between the effect of ivabradine and baseline
heart rate.
The clinical implications of our findings reflect the
importance of heart rate as we have previously reported (7).
When a resting heart rate 70 beats/min is observed in
patients with systolic heart failure in sinus rhythm, the
background pharmacological treatment should be re-
viewed, in particular focusing on the beta-blocker ther-
apy. If an increase of the dose of the beta-blocker can be
achieved and results in lowering the heart rate below 70
beats/min, therapy with beta-blocker alone is appropri-
ate. If this goal is not achievable clinically, the addition of
ivabradine will result in reduction of the risk of future
cardiovascular events.
Study limitations. As a post-hoc subgroup analysis, our
findings should be treated cautiously. Our analysis was
based on background treatments as optimized by the inves-
tigators and not based on a randomized allocation. How-
ever, the comparisons between ivabradine and placebo
within each beta-blocker category, and the comparisons of
treatment effects between beta-blocker categories, are ran-
domized. Inevitably, the numbers of subjects within each
beta-blocker category is much smaller than the overall
sample size, and hence, power to detect treatment effects
and particularly between–beta-blocker category differences
in treatment effects is no more than moderate.
Conclusions
Among patients with systolic heart failure, the dose to
which a beta-blocker can be titrated is dependent on patient
comorbidities and other demographics. By adding the heart
rate–lowering agent, ivabradine, in patients whose heart rate
exceeds 70 beats/min despite beta-blockade (as well as
among those who cannot tolerate beta-blockade), the addi-
tional heart rate reduction is beneficial. The magnitude of
heart rate reduction by ivabradine beyond what is achieved
by a beta-blocker, rather than background beta-blocker
dose, primarily determines subsequent outcome.
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